Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
R Roskoski Jr - Pharmacological research, 2019 - Elsevier
Cyclins and cyclin-dependent protein kinases (CDKs) are important proteins that are
required for the regulation and expression of the large number of components necessary for …
required for the regulation and expression of the large number of components necessary for …
Immune checkpoint inhibitors: basics and challenges
Cancer is one of the most deadly diseases in the modern world. The last decade has
witnessed dramatic advances in cancer treatment through immunotherapy. One extremely …
witnessed dramatic advances in cancer treatment through immunotherapy. One extremely …
Targeting mitosis in cancer: emerging strategies
The cell cycle is an evolutionarily conserved process necessary for mammalian cell growth
and development. Because cell-cycle aberrations are a hallmark of cancer, this process has …
and development. Because cell-cycle aberrations are a hallmark of cancer, this process has …
Cellular pathways in response to ionizing radiation and their targetability for tumor radiosensitization
P Maier, L Hartmann, F Wenz, C Herskind - International journal of …, 2016 - mdpi.com
During the last few decades, improvements in the planning and application of radiotherapy
in combination with surgery and chemotherapy resulted in increased survival rates of tumor …
in combination with surgery and chemotherapy resulted in increased survival rates of tumor …
PI3K/Akt signaling in osteosarcoma
Osteosarcoma (OS) is the most common nonhematologic bone malignancy in children and
adolescents. Despite the advances of adjuvant chemotherapy and significant improvement …
adolescents. Despite the advances of adjuvant chemotherapy and significant improvement …
[HTML][HTML] Roscovitine in cancer and other diseases
Abstract Roscovitine [CY-202,(R)-Roscovitine, Seliciclib] is a small molecule that inhibits
cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a …
cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a …
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
R Roskoski Jr - Pharmacological research, 2016 - Elsevier
Cyclins and cyclin-dependent protein kinases (CDKs) are important regulatory components
that are required for cell cycle progression. The levels of the cell cycle CDKs are generally …
that are required for cell cycle progression. The levels of the cell cycle CDKs are generally …
Protein degradation technology: a strategic paradigm shift in drug discovery
Targeting pathogenic proteins with small-molecule inhibitors (SMIs) has become a widely
used strategy for treating malignant tumors. However, most intracellular proteins have been …
used strategy for treating malignant tumors. However, most intracellular proteins have been …
Pharmacological targeting of cell cycle, apoptotic and cell adhesion signaling pathways implicated in chemoresistance of cancer cells
Chemotherapeutic drugs target a physiological differentiating feature of cancer cells as they
tend to actively proliferate more than normal cells. They have well-known side-effects …
tend to actively proliferate more than normal cells. They have well-known side-effects …
Identification of atuveciclib (BAY 1143572), the first highly selective, clinical PTEFb/CDK9 inhibitor for the treatment of cancer
U Lücking, A Scholz, P Lienau, G Siemeister… - …, 2017 - Wiley Online Library
Selective inhibition of exclusively transcription‐regulating PTEFb/CDK9 is a promising new
approach in cancer therapy. Starting from lead compound BAY‐958, lead optimization …
approach in cancer therapy. Starting from lead compound BAY‐958, lead optimization …